Cathy R. Smith - 07 May 2026 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Reporting relationship: Director
Issuer ticker: BSX
Reported as of: 07 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 May 2026, 16:33:14 UTC
Prior SEC filing: 17 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Susan Thompson, Attorney-in-Fact

Key filing fact

Cathy R. Smith filed Form 4 for BOSTON SCIENTIFIC CORP (BSX) on 11 May 2026.

Key facts

This page summarizes Cathy R. Smith's Form 4 filing for BOSTON SCIENTIFIC CORP (BSX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 11 May 2026, 16:33.

Change

Previous filing in this sequence was filed on 17 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001322028 Primary reporting owner

Smith Cathy R

Relationship: Director
Address: 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH
Signature: /s/ Susan Thompson, Attorney-in-Fact
Signature date: 11 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BSX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +3,800
Change %: +432%
Price: $0.000000^*
Shares after: 4,679
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,800
Exercise price
Footnotes: F1, F2, F3

BSX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +2,209
Change %: +47%
Price: $0.000000^*
Shares after: 6,888
Date: 07 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,209
Exercise price
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

Footnote F2

Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

Footnote F3

Annual equity award in the form of deferred stock units vesting in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Director service in accordance with the Company's Non-Employee Director Deferred Compensation Plan.

Footnote F4

Deferred stock units were granted in lieu of 100% yearly cash compensation and vest in full upon the next annual meeting of stockholders. Vested shares of stock will be issued to the reporting person following the reporting person's separation from Board of Directors service in accordance with the Company's Non-Employee Director Deferred Compensation Plan. Reflects a value of $125,000 (representing 100% of the amount of the non-employee director compensation program's cash retainer) divided by the closing price of the common stock on the date of grant.